Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance.
Intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD) patients comprise at least 20% of treated patients and are at high risk for coronary artery abnormalities. If identified early in the course of the disease, such patients may benefit from additional anti-inflammatory therapy. The aim of this study was to compare the transcript abundance between IVIG resistant and -responsive KD patients, to identify biomarkers that might differentiate between these two groups and to generate new targets for therapies in IVIG resistant KD patients. We compared the transcript abundance profiles of whole-blood RNA on Agilent arrays from acute and convalescent KD subjects and age-similar, healthy controls. KD subjects were stratified as IVIG resistant or -responsive based on response to initial IVIG therapy. Transcript abundance was higher for IL-1 pathway genes (IL-1 receptor, interleukin receptor associated kinase, p38 mitogen-activated protein kinase), and MMP-8. These findings point to candidate biomarkers that may predict IVIG resistance in acute KD patients. The results also underscore the importance of the IL-1 pathway as a mediator of inflammation in KD and suggest that IL-1 or its receptor may be reasonable targets for therapy, particularly for IVIG resistant patients.
Fury
Wen
W
Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Tremoulet
Adriana H
AH
Watson
Virginia E
VE
Best
Brookie M
BM
Shimizu
Chisato
C
Hamilton
Jennifer
J
Kanegaye
John T
JT
Wei
Yi
Y
Kao
Chiayi
C
Mellis
Scott
S
Lin
Calvin
C
Burns
Jane C
JC
D015703:Antigens, CD / Q000235:genetics; D015415:Biomarkers / Q000097:blood; D015815:Cell Adhesion Molecules / Q000235:genetics; D002648:Child; D002675:Child, Preschool; D015922:Complement C1q / Q000235:genetics; D004351:Drug Resistance / Q000235:genetics*; D005260:Female; D058851:GPI-Linked Proteins / Q000235:genetics; D015870:Gene Expression / Q000235:genetics; D020869:Gene Expression Profiling; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007223:Infant; D007375:Interleukin-1 / Q000378:metabolism; D053592:Interleukin-1 Receptor-Associated Kinases / Q000235:genetics; D008297:Male; D020784:Matrix Metalloproteinase 8 / Q000097:blood / Q000235:genetics; D009080:Mucocutaneous Lymph Node Syndrome / Q000097:blood / Q000188:drug therapy* / Q000235:genetics*; D016328:NF-kappa B / Q000235:genetics; D020411:Oligonucleotide Array Sequence Analysis; D012333:RNA, Messenger / Q000032:analysis* / Q000235:genetics; D053574:Receptors, Interleukin-1 Type II / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D009418:S100 Proteins / Q000235:genetics; D015398:Signal Transduction / Q000235:genetics; D014158:Transcription, Genetic / Q000235:genetics*; D015854:Up-Regulation / Q000235:genetics
D015703:Antigens, CD; D015415:Biomarkers; C069847:CD66 antigens; C504120:CEACAM8 protein, human; D015815:Cell Adhesion Molecules; D058851:GPI-Linked Proteins; C508592:IL1R2 protein, human; D016756:Immunoglobulins, Intravenous; D007375:Interleukin-1; D016328:NF-kappa B; D012333:RNA, Messenger; D053574:Receptors, Interleukin-1 Type II; D009418:S100 Proteins; D015922:Complement C1q; D053592:Interleukin-1 Receptor-Associated Kinases; D020784:Matrix Metalloproteinase 8